Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes Journal Article

Local Library Link: Find It @ Loyola

Authors: Ramanathan, K.; Abel, J. G.; Park, J. E.; Fung, A.; Mathew, V; Taylor, C. M.; Mancini, G. B. J.; Gao, M.; Ding, L.; Verma, S; Humphries, K. H.; Farkouh, M. E.
Article Title: Surgical Versus Percutaneous Coronary Revascularization in Patients With Diabetes and Acute Coronary Syndromes
Abstract: BACKGROUND: Randomized trial data support the superiority of coronary artery bypass grafting (CABG) surgery over percutaneous coronary intervention (PCI) in diabetic patients with multivessel coronary artery disease (MV-CAD). However, whether this benefit is seen in a real-world population among subjects with stable ischemic heart disease (SIHD) and acute coronary syndromes (ACS) is unknown. OBJECTIVES: The main objective of this study was to assess the generalizability of the FREEDOM (Future REvascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multi-vessel Disease) trial in real-world practice among patients with diabetes mellitus and MV-CAD in residents of British Columbia, Canada. Additionally, the study evaluated the impact of mode of revascularization (CABG vs. PCI with drug-eluting stents) in diabetic patients with ACS and MV-CAD. METHODS: In a large population-based database from British Columbia, this study evaluated major cardiovascular outcomes in all diabetic patients who underwent coronary revascularization between 2007 and 2014 (n = 4,661, 2,947 patients with ACS). The primary endpoint (major adverse cardiac or cerebrovascular events [MACCE]) was a composite of all-cause death, nonfatal myocardial infarction, and nonfatal stroke. The risk of MACCE with CABG or PCI was compared using multivariable adjustment and a propensity score model. RESULTS: At 30-days post-revascularization, for ACS patients the odds ratio for MACCE favored CABG 0.49 (95% confidence interval [CI]: 0.34 to 0.71), whereas among SIHD patients MACCE was not affected by revascularization strategy (odds ratio: 1.46; 95% CI: 0.71 to 3.01; pinteraction lt;0.01). With a median follow-up of 3.3 years, the late (31-day to 5-year) benefit of CABG over PCI no longer varied by acuity of presentation, with a hazard ratio for MACCE in ACS patients of 0.67 (95% CI: 0.55 to 0.81) and the hazard ratio for SIHD patients of 0.55 (95% CI: 0.40 to 0.74; pinteraction = 0.28). CONCLUSIONS: In diabetic patients with MV-CAD, CABG was associated with a lower rate of long-term MACCE relative to PCI for both ACS and SIHD. A well-powered randomized trial of CABG versus PCI in the ACS population is warranted because these patients have been largely excluded from prior trials.
Journal Title: Journal of the American College of Cardiology
Volume: 70
Issue: 24
ISSN: 1558-3597; 0735-1097
Publisher: Elsevier Inc  
Journal Place: United States
Date Published: 2017
Start Page: 2995
End Page: 3006
Language: eng
DOI/URL:

S0735-1097(17)41258-7
Notes: LR: 20171227; CI: Copyright (c) 2017; JID: 8301365; OTO: NOTNLM; 2016/10/21 00:00 [received]; 2017/09/29 00:00 [revised]; 2017/10/10 00:00 [accepted]; 2017/12/16 06:00 [entrez]; 2017/12/16 06:00 [pubmed]; 2017/12/28 06:00 [medline]; ppublish